Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Radiotherapy and oncology[TA])
7,369 results
  • Biological effects in normal cells exposed to FLASH dose rate protons. [Journal Article]
  • RORadiother Oncol 2019 Mar 05
  • Buonanno M, Grilj V, Brenner DJ
  • CONCLUSIONS: In normal lung fibroblasts proton dose rate had little impact on acute effects, but significantly influenced the expression of long-term biological responses in vitro. Compared to conventional dose rates, protons delivered at FLASH dose rates mitigated such delayed detrimental effects.
  • Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. [Journal Article]
  • RORadiother Oncol 2019; 132:79-84
  • van der Sande ME, Hupkens BJP, … Breukink SO
  • CONCLUSIONS: This is the first study to investigate the late dose-volume effects of radiotherapy specifically on the anorectal function in rectal cancer patients. One-third of the patients had major LARS and the most frequent reported complaints were clustering and faecal urgency. Additionally, we observed trends towards worse long-term anorectal function after higher anal sphincter complex radiotherapy dose. However, this should be evaluated on a larger scale. Future efforts to minimise the dose to the sphincters could possibly reduce the impact of radiotherapy on the anorectal function.
  • Postmastectomy radiation therapy for triple negative, node-negative breast cancer. [Journal Article]
  • RORadiother Oncol 2019; 132:48-54
  • Haque W, Verma V, … Teh BS
  • CONCLUSIONS: In the largest study to date evaluating the use of PMRT in patients with node-negative TNBC, the use of PMRT was low in patients with T1 and T2 disease. Additionally, while an OS benefit was observed with the use of PMRT in patients with T3 disease, there was no benefit with the use of PMRT in other T stage groups. Further prospective studies are recommended to further elucidate the benefit on PMRT in patients with node-negative TNBC.
New Search Next